Company: DARI Motion, Inc.
Patent Number: US 12700103
Title: System and method for image data analysis for objective analysis of joint motion data
Advancing Biomechanical Assessments
DARI Motion, Inc. recently secured a patent for an advanced system designed to objectively analyze image data for joint motion evaluation. This invention won the Patent of the Month for the Nebraska state for the month of September 2026 granted by Swanson Reed because it successfully standardizes human movement assessments, offering a highly accurate and markerless alternative to historically subjective orthopedic evaluations.
The core innovation of this invention lies in its complete departure from traditional and manual joint assessments. Historically, physical therapists and medical professionals relied on tools like goniometers and subjective visual scales to evaluate a patient’s mobility, a practice that frequently resulted in inconsistent measurements. This newly patented method resolves this issue by utilizing a markerless motion capture system to record and extract kinetic and kinematic data automatically. The system then applies advanced regression models to compare an individual’s movements against a comprehensive population database. By generating a definitive and objective score for joint motion, the system removes the variability of human estimation and provides medical professionals with precise data to guide physical rehabilitation and athletic training.
R&D Tax Credit Eligibility for Motion Capture Software Development
The practical applications of this patent demonstrate exactly the type of technological advancement that may be eligible for the Research and Development (R&D) tax credit in the United States. Integrating markerless motion tracking software with population-based regression models requires extensive engineering, algorithmic testing, and data validation. Resolving the technical uncertainties associated with real-time image data extraction and biomechanical scoring aligns closely with the requirements of the IRS four-part test. Companies that invest capital into the systematic experimentation necessary to build, test, and improve these automated clinical evaluation platforms can likely claim their related software development and engineering expenses for valuable R&D tax incentives.
